Acasunlimab

DARZALEX (daratumumab) generated $3.24 billion in global net sales during Q1 2025, with $1.83 billion from U.S. markets and $1.41 billion internationally.

Johnson & Johnson has decided not to exercise its option to license Genmab's HexaBody-CD38 antibody therapeutic, despite promising clinical efficacy data in multiple myeloma patients.

A phase 2 trial identified dendritic cells (DCs) as critical in follicular lymphoma (FL) progression under rituximab plus lenalidomide (R2) treatment, highlighting the need for new strategies.